Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf025 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Chengjuan Fan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Meningeal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wu Jieping Medical Foundation, Beijing Association for Cancer Control and Prevention.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Leptomeningeal metastases (LMs) are serious complications of non-small cell lung cancer (NSCLC). This study aimed to investigate the safety and efficacy of intrathecal immune checkpoint inhibitors (ICIs) in treating NSCLC-LM.
Methods
We conducted this prospective phase 1 study (ChiCTR2200062245) using a traditional “3+3” design with intrathecal sintilimab (dose escalation 10, 20, 30, and 40 mg) for NSCLC-LM patients who had progressed from targeted therapy and intrathecal pemetrexed. The primary study endpoints were safety and recommended dose, and the secondary endpoints included clinical response rate, progression-free survival (PFS), intracranial progression-free survival (iPFS), and overall survival (OS).
Results
No dose-limiting toxicity was found at 10, 20, 30, and 40 mg for intrathecal sintilimab. Therefore, sintilimab 40 mg was recommended for intrathecal injection. A total of 19 patients were enrolled in this study. The median age at diagnosis of LM was 53 years. The overall incidence of adverse events (AEs) was 68.4%, and rash (n = 4, 21.1%) was the most common AEs, which returned to normal after symptomatic treatment. As 1 patient was lost to follow-up and 18 patients could be evaluated for efficacy, the clinical response rate was 38.9% (7/18). Median PFS was 3.5 months (95% CI: 2.7–4.2 months), median iPFS was 3.5 months (95% CI: 1.3–5.6 months), and median OS was 11.5 months (95% CI: 0.0–25.4 months).
Conclusions
Intrathecal ICIs for NSCLC-LM patients are safe, and the recommended dose of sintilimab is 40 mg. Intrathecal sintilimab for NSCLC-LM failed from multi-line therapies, showed potential effectiveness in some patients, and is worthy of further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
ORCID-Profile: Tao Xin
Förderung
- Wu Jieping Medical Foundation
- Beijing Association for Cancer Control and Prevention
Zitieren
APA
Fan, C., Hu, Y., Teng, C., Lv, Y., Song, X., Shen, W., Jiang, Q., Huang, D., Du, L., Wang, G., Du, Y., Man, S., Zhang, Z., Zhang, J., Li, L., & Xin, T. (2025). Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study). Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf025
Vancouver
Fan C, Hu Y, Teng C, Lv Y, Song X, Shen W, et al. Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study). Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf025
BibTeX
@article{Fan2025,
author = {Fan, Chengjuan and Hu, Yuanyuan and Teng, Chong and Lv, Yanju and Song, Xiaowei and Shen, Weixi and Jiang, Qiuying and Huang, Dayong and Du, Lina and Wang, Guohua and Du, Yang and Man, Siqi and Zhang, Zhichao and Zhang, Jing and Li, Li and Xin, Tao},
title = {Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf025}
}
EUVIMED